This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Percentage of participants with dose-limiting toxicities (DLTs)
Timeframe: Up to 4 weeks
Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)
Timeframe: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Frequency of SAEs/AEs leading to discontinuation of AZD4512
Timeframe: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters
Timeframe: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
AstraZeneca Clinical Study Information Center